Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:EBS NASDAQ:GERN NASDAQ:MYGN NASDAQ:NVAX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEBSEmergent Biosolutions$7.57-3.4%$7.54$4.02▼$12.73$405.94M2.041.24 million shs522,840 shsGERNGeron$1.38-1.8%$1.35$1.09▼$4.83$877.28M0.6312.27 million shs3.14 million shsMYGNMyriad Genetics$6.76-0.7%$5.36$3.76▼$29.30$627.56M1.931.72 million shs555,450 shsNVAXNovavax$7.78+5.1%$7.47$5.01▼$15.22$1.26B2.686.76 million shs5.79 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEBSEmergent Biosolutions-4.62%-8.51%+31.52%+29.35%+6.52%GERNGeron-4.76%-0.71%+15.70%-10.26%-68.18%MYGNMyriad Genetics-1.45%+14.67%+70.85%+38.21%-75.24%NVAXNovavax-1.99%-2.37%+9.63%+5.87%-41.59%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEBSEmergent Biosolutions$7.57-3.4%$7.54$4.02▼$12.73$405.94M2.041.24 million shs522,840 shsGERNGeron$1.38-1.8%$1.35$1.09▼$4.83$877.28M0.6312.27 million shs3.14 million shsMYGNMyriad Genetics$6.76-0.7%$5.36$3.76▼$29.30$627.56M1.931.72 million shs555,450 shsNVAXNovavax$7.78+5.1%$7.47$5.01▼$15.22$1.26B2.686.76 million shs5.79 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEBSEmergent Biosolutions-4.62%-8.51%+31.52%+29.35%+6.52%GERNGeron-4.76%-0.71%+15.70%-10.26%-68.18%MYGNMyriad Genetics-1.45%+14.67%+70.85%+38.21%-75.24%NVAXNovavax-1.99%-2.37%+9.63%+5.87%-41.59%Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEBSEmergent Biosolutions$1.04B0.39$1.75 per share4.32$10.05 per share0.75GERNGeron$76.99M11.39N/AN/A$0.41 per share3.35MYGNMyriad Genetics$837.60M0.75$1.06 per share6.38$4.17 per share1.62NVAXNovavax$682.16M1.85N/AN/A$0.23 per share33.80Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEBSEmergent Biosolutions-$190.60M$2.453.113.65N/A16.38%24.63%8.97%11/5/2025 (Estimated)GERNGeron-$174.57M-$0.13N/AN/AN/A-53.52%-31.37%-16.01%11/6/2025 (Estimated)MYGNMyriad Genetics-$127.30M-$4.28N/AN/AN/A-47.45%-5.17%-3.44%11/6/2025 (Estimated)NVAXNovavax-$187.50M$2.283.4097.190.1039.20%-142.33%28.65%11/11/2025 (Estimated)Latest EBS, NVAX, GERN, and MYGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025EBSEmergent Biosolutions-$0.26$0.16+$0.42-$0.22$148.55 million$140.90 million8/6/2025Q2 2025GERNGeron-$0.03-$0.02+$0.01-$0.02$47.30 million$49.04 million8/6/2025Q2 2025NVAXNovavax-$0.07$0.62+$0.69$0.62$149.19 million$239.24 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEBSEmergent BiosolutionsN/AN/AN/AN/AN/AGERNGeronN/AN/AN/AN/AN/AMYGNMyriad GeneticsN/AN/AN/AN/AN/ANVAXNovavaxN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEBSEmergent Biosolutions1.255.663.00GERNGeron0.467.876.79MYGNMyriad GeneticsN/A1.421.28NVAXNovavax5.932.362.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEBSEmergent Biosolutions78.40%GERNGeron73.71%MYGNMyriad Genetics99.02%NVAXNovavax53.04%Insider OwnershipCompanyInsider OwnershipEBSEmergent Biosolutions3.20%GERNGeron7.42%MYGNMyriad Genetics2.10%NVAXNovavax1.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEBSEmergent Biosolutions2,42053.35 million51.64 millionOptionableGERNGeron70638.02 million590.68 millionOptionableMYGNMyriad Genetics2,70093.04 million91.09 millionOptionableNVAXNovavax1,990162.42 million160.80 millionOptionableEBS, NVAX, GERN, and MYGN HeadlinesRecent News About These CompaniesNovavax, Inc. (NVAX) Presents At Cantor Global Healthcare Conference 2025 Transcript1 hour ago | seekingalpha.comNuvaxovid® Now Approved in Japan Triggering Takeda Milestone PaymentSeptember 4 at 8:00 AM | prnewswire.comNovavax ‘applauds’ President Trump’s call for available COVID-19 vaccine dataSeptember 4 at 2:44 AM | msn.comNovavax to Participate in the Cantor Global Healthcare ConferenceSeptember 3 at 10:54 AM | finance.yahoo.comOMERS ADMINISTRATION Corp Takes $1.28 Million Position in Novavax, Inc. $NVAXSeptember 3 at 4:59 AM | marketbeat.comNovavax, Inc. (NASDAQ:NVAX) Receives $14.29 Consensus PT from AnalystsSeptember 3 at 2:25 AM | americanbankingnews.comOptimistic Outlook on Novavax: Strategic Positioning and Vaccine Developments Drive Buy RatingSeptember 2 at 8:11 AM | tipranks.comRafferty Asset Management LLC Sells 80,502 Shares of Novavax, Inc. $NVAXSeptember 2 at 5:05 AM | marketbeat.comInvesco Ltd. Boosts Stake in Novavax, Inc. $NVAXSeptember 2 at 3:30 AM | marketbeat.comFY2025 Earnings Forecast for Novavax Issued By HC WainwrightSeptember 2 at 2:28 AM | marketbeat.comHC Wainwright Comments on Novavax FY2025 EarningsSeptember 2 at 2:27 AM | americanbankingnews.comNuveen LLC Purchases New Position in Novavax, Inc. $NVAXSeptember 1 at 3:34 AM | marketbeat.comNovavax, Inc. (NASDAQ:NVAX) Given Consensus Recommendation of "Hold" by BrokeragesSeptember 1 at 2:09 AM | marketbeat.comQ3 Earnings Forecast for Novavax Issued By HC WainwrightAugust 31, 2025 | marketbeat.comHC Wainwright Reaffirms "Buy" Rating for Novavax (NASDAQ:NVAX)August 30, 2025 | marketbeat.comKohl’s, Bill.com, Novavax, Jazz, Nvidia: Trending by AnalystsAugust 30, 2025 | tipranks.comHC Wainwright Initiates Coverage on Novavax (NASDAQ:NVAX)August 30, 2025 | americanbankingnews.comWhat is HC Wainwright's Estimate for Novavax Q3 Earnings?August 30, 2025 | americanbankingnews.comNovavax, Inc. (NVAX) Wins FDA Approval for Nuvaxovid BLAAugust 29, 2025 | finance.yahoo.comRobert Kennedy Jr. Announces End Of FDA Covid Mandates – Clears Moderna, Pfizer, Novavax For High-Risk GroupsAugust 28, 2025 | msn.comNovavax (NVAX) Is Up After FDA Approves Updated Nuvaxovid for Key High-Risk Groups—What's ChangedAugust 28, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025An Atomic Sized Surge Is Brewing for NuScale Power Stock PriceBy Thomas Hughes | August 11, 2025Big Rallies Brewing? 3 Analyst Favorites to Watch CloselyBy Nathan Reiff | August 18, 2025EBS, NVAX, GERN, and MYGN Company DescriptionsEmergent Biosolutions NYSE:EBS$7.56 -0.27 (-3.38%) As of 03:56 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.Geron NASDAQ:GERN$1.38 -0.03 (-1.79%) As of 03:56 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.Myriad Genetics NASDAQ:MYGN$6.76 -0.05 (-0.66%) As of 03:56 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.Novavax NASDAQ:NVAX$7.78 +0.38 (+5.07%) As of 03:56 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dollar Tree Plunges Into Buy-Zone: A Robust Rebound Is Expected Zscaler Shares Can Hit a Fresh High Before Year-End Why Qualcomm Is Outperforming NVIDIA After Months of Lagging Alphabet Stock Surges After Dodging Harsh Antitrust Remedies Wall Street Punishes Dell's Record Quarter: Why They Are Wrong Ambarella's Earnings Prove Its Edge AI Strategy Is a Winner Taiwan Semiconductor Falls on China News—Buy The Dip? CrowdStrike Tests $412 Support as Options Traders Turn Bullish Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
